メラノーマ患者におけるイマチニブメシル酸塩とペムブロリズマブの併用療法

基本情報

NCT ID: NCT04546074
ステータス: 不明
試験のフェーズ: 第1/第2相
試験タイプ: 介入
目標被験者数: 22
治験依頼者名: Keio University

概要

This is an open-labelled single arm trial of pembrolizumab and imatinib mesylate in subjects with unresectable or metastatic KIT-mutant melanoma that are refractory to standard therapy. The phase Ib and II study will be conducted to evaluate the safety, tolerability and response rate data of this combination therapy. KIT-mutant tumors will be confirmed in previously biopsied tumors. This analysis will be done by next-generation sequencing.

対象疾患

Melanoma

介入

Pembrolizumab and Imatinib mesylate(DRUG)

依頼者（Sponsor）

MSD株式会社(INDUSTRY)

Keio University(OTHER)

Ohara(INDUSTRY)

実施施設 (1)

慶應義塾大学病院

Shinjuku, Tokyo, Japan(RECRUITING)